CLEVELAND, May 22, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the clinical team at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis has treated its 1,000th patient using MRIdian MR-guided radiation therapy.
Siteman Cancer Center helped pioneer MR-guided radiation therapy, becoming the first center to treat patients with MRIdian in January 2014. Siteman also leads the industry as the first to perform adaptive radiation therapy under MR-guidance. MRIdian's on-table adaptive capability and automated beam gating, now routinely practiced at Siteman, allows clinicians to personalize the radiation delivery by adapting to daily changes in a patient's anatomy, while its real-time tissue tracking and beam control allow greater precision to the delivery of radiation therapy. As the use of MR-guided radiation therapy expanded, Siteman acquired a second MRIdian System – the MRIdian Linac – in November 2017, following FDA-clearance of this next-generation technology from ViewRay. The new technology features MRI-guidance combined with linear accelerator delivery.
"We commend the Siteman team for its continued adoption and advancement of innovative technology to further patient care, and congratulate them on reaching this exciting milestone," said Scott Drake, President and Chief Executive Officer of ViewRay. "The center's trailblazing research and cutting-edge treatments have played a big role in the clinical acceptance and growing adoption of MRI-guided radiation therapy, which, in turn, has benefitted not just the 1,000 cancer patients at Siteman but many others around the world."
Ad Statistics
Times Displayed: 173517
Times Visited: 3165 For those who need to move fast and expand clinical capabilities -- and would love new equipment -- the uCT 550 Advance offers a new fully configured 80-slice CT in up to 2 weeks with routine maintenance and parts and Software Upgrades for Life™ included.
"The location of tumors in the body can fluctuate slightly in response to subtle movements, such as breathing, potentially disrupting the precise target of a radiation beam," said Jeff Michalski, M.D., Carlos A. Perez Distinguished Professor, Vice Chair and Director of Clinical Programs in Radiation Oncology at Siteman Cancer Center and Washington University School of Medicine. "MR-guided radiation therapy allows us to visualize and precisely track the contours of a patient's tumor as radiation therapy is being delivered. With this enhanced visibility, we can quickly adjust the dose of radiation in real time to account for changes in the position of a tumor. This capability helps to ensure that the maximum dose reaches the tumor and incidental exposure to surrounding healthy tissues is minimized."
